New Therapeutic Targets and Treatments for Metastatic Prostate Cancer

Home

Online Conferences

Editorial Board

Our Partners

Registration (free!)

Français - August 20, 2011

CME on Prostate Health is dedicated to online CME conferences, courses and presentations (slides with voice over) on prostate health, given by local and international experts. Its mission is to keep you up-to-date with the most recent developments on prostate health.

Presentation

"New Therapeutic Targets and Treatments for Metastatic Prostate Cancer"
Dr. William Nelson (biography)
English - 2005-06-27 - 54 minutes

Summary :
Scher and colleagues have attempted to institute the notion of disease states in patients with prostate cancer. These are recurrent prostate cancer after local therapy (no metastasis), metastatic prostate cancer not yet treated, androgen independent prostate cancer (no metastasis), and androgen independent metastatic prostate cancer. Several therapeutic treatments demonstrate to be more suitable for some states while less suitable for others. This patient stratification may aid physicians in choosing a therapy.

Dr. Nelson reviews several treatment approaches such as androgen blockade/deprivation, tubulin targeting, radioisotopes for the treatment of bony metastasis, immunotherapy, and gene therapy.

Furthermore, he introduces novel targeted therapies currently being investigated. These include DNA methylation, and molecular therapy.

Copyright © E-MedHosting.com Inc.

Learning objectives :
After viewing this presentation, participants will be able to discuss:
- Different disease states;
- Various therapeutic treatments and targets;
- Points to consider for these therapeutic treatments and targets.

Bibliographic references :
Bill-Axelson A., Holmberg L., Ruutu M., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Busch C., Nordling S., Garmo H., Palmgren J., Adami H.-O., Norlén B. J., Johansson J.-E., the Scandinavian Prostate Cancer Group Study No. 4 Radical Prostatectomy versus Watchful Waiting in Early Prostate CancerN Engl J Med 2005; 352:1977-1984, May 12, 2005.

D'Amico A. V., Chen M.-H., Roehl K. A., Catalona W. J.Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyN Engl J Med 2004; 351:125-135, Jul 8, 2004

Mark A. Rubin, Mathew Putzi, Neil Mucci, David C. Smith, Kirk Wojno, Susan Korenchuk, and Kenneth J. Pienta Rapid ("Warm") Autopsy Study for Procurement of Metastatic Prostate Cancer Clin Cancer Res 2000 6: 1038-1045.

Matthew R. Smith, Fairooz Kabbinavar, Fred Saad, Arif Hussain, Marc C. Gittelman, David L. Bilhartz, Chris Wynne, Robin Murray, Norman R. Zinner, Claude Schulman, Ronald Linnartz, Ming Zheng, Carsten Goessl, Yong-Jiang Hei, Eric J. Small, Richard Cook, Celestia S. Higano Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate CancerJCO May 1 2005: 2918-2925.

Howard I. Scher and Glenn Heller Clinical states in prostate cancer: toward a dynamic model of disease progression Urology Volume 55, Issue 3 , March 2000, Pages 323-327

Nelson W. G., De Marzo A. M., Isaacs W. B.Mechanisms of Disease: Prostate CancerN Engl J Med 2003; 349:366-381, Jul 24, 2003.

Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., the TAX 327 Investigators Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerN Engl J Med 2004; 351:1502-1512, Oct 7, 2004

Petrylak D. P., Tangen C. M., Hussain M. H.A., Lara P. N. Jr., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D.Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerN Engl J Med 2004; 351:1513-1520, Oct 7, 2004.

Fred Saad, Donald M. Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner, Louis Lacombe, Joseph L. Chin, Jeferson J. Vinholes, J. Allen Goas, and Ming ZhengLong-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer J Natl Cancer Inst 2004; 96: 879-882.

Michael A. Carducci, Robert J. Padley, Jurgen Breul, Nicholas J. Vogelzang, Bernard A. Zonnenberg, Danai D. Daliani, Claude C. Schulman, Azmi A. Nabulsi, Rod A. Humerickhouse, Mark A. Weinberg, Jennifer L. Schmitt, Joel B. Nelson Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled TrialJCO Feb 15 2003: 679-689.

Theodore L. DeWeese, Henk van der Poel, Shidong Li, Bahar Mikhak, Renee Drew, Marti Goemann, Ulrike Hamper, Robert DeJong, Nicholas Detorie, Ronald Rodriguez, Thomas Haulk, Angelo M. DeMarzo, Steven Piantadosi, D. C. Yu, Yu Chen, Daniel R. Henderson, Michael A. Carducci, William G. Nelson, and Jonathan W. Simons A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation TherapyCancer Res. 2001 61: 7464-7472.

Samuel R. Denmeade, Carsten M. Jakobsen, Samuel Janssen, Saeed R. Khan, Elizabeth S. Garrett, Hans Lilja, S. Brogger Christensen, and John T. IsaacsProstate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer J Natl Cancer Inst 2003; 95: 990-1000.

Isabelle Sansal, William R. Sellers The Biology and Clinical Relevance of the PTEN Tumor Suppressor PathwayJCO Jul 15 2004: 2954-2963.

Herman J. G., Baylin S. B.Mechanisms of Disease: Gene Silencing in Cancer in Association with Promoter HypermethylationN Engl J Med 2003; 349:2042-2054, Nov 20, 2003.

Srinivasan Yegnasubramanian, Jeanne Kowalski, Mark L. Gonzalgo, Marianna Zahurak, Steven Piantadosi, Patrick C. Walsh, G. Steven Bova, Angelo M. De Marzo, William B. Isaacs, and William G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate CancerCancer Res. 2004 64: 1975-1986

Login

	Please enter your username and password to access all the resources CMEonProstateHealth.com has to offer.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

	Would you like to know more about prostate health? Find what you are looking for by typing a keyword !
	Look for :

	In...

Read our newsletters

Newsletter 132 (2005-03-02)

Newsletter 118 (2005-01-14)

Newsletter 82 (2004-09-09)

CMEonProstateHealth is owned by E-MedHosting.com.

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.